Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Chemical Mutagenesis

Financiado

Cerrado

Chemical mutagenesis a powerful tool for the creation of a library of nanobodie...

Chemical mutagenesis a powerful tool for the creation of a library of nanobodies Finding a non-aggressive treatment against Cancer is one of the most important challenges that medicine has nowadays. Immunotherapy has emerged as one of the best options to overcome the current problems of chemotherapy. By the us... ver más

29/02/2024

THE CHANCELLOR MAS...

213K€

Presupuesto del proyecto: 213K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-02-29

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE CHANCELLOR MASTERS AND S...

212.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-124010OB-I00 FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBR... 145K€ Cerrado

PAVE A nanovaccine Approach for the treatment of Pancreatic Cance... 4M€ Cerrado

ImmuneSynapsEngagers Immune Synapse Engagement as a Novel Approach for Cancer Imm... 2M€ Cerrado

RESYNC Functional chemical reprogramming of cancer cells to induce... 3M€ Cerrado

RTC-2017-6604-1 Herramientas para el pronóstico y monitorización de la respu... 727K€ Cerrado

PID2020-119368RB-I00 NANO-INMUNOTERAPIAS COMBINADAS BASADAS EN SIRNA APLICADAS... 295K€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2021-04-19
Fecha Fin: 2024-02-29

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 213K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Finding a non-aggressive treatment against Cancer is one of the most important challenges that medicine has nowadays. Immunotherapy has emerged as one of the best options to overcome the current problems of chemotherapy. By the use of monoclonal antibodies (mAb), immunotherapy is able to block regulatory checkpoints and, therefore, the immune response against tumoral cells could be modulated. Trastuzumab, pembrolizumab and nivolumab are some of the mAb approved by the Food and Drug Administration (FDA) for their use against several cancers. Trastuzumab recognizes the overexpressed protein HER2 in breast cancer, whereas the pembrolizumab and the nivolumab recognize the Programmed Cell Death-1 (PD-1) receptor and are used in several cancers such as refractory melanoma. However, there are reported important issues concerning cancer resistance to these mAb, thus, modifying their characteristics became necessary. Unlike it happens with small molecules, there are several limitations to functionalize an antibody to improve its characteristics. In this context, chemical mutagenesis turns into a powerful tool because it allows the modification of an antibody directly with highly specific chemical reactions, and achieve changes onto its structure that would not be possible by using other techniques such as protein engineering and genetic encoding. In this proposal I envision the use of nanobodies able to recognize HER-2 protein and PD-1 receptor in order to improve their affinity to their targets by chemical mutagenesis via alanyl radical. The success of this project would provide solutions to the cancer resistance to current immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores